Institution
University of Modena and Reggio Emilia
Education•Modena, Italy•
About: University of Modena and Reggio Emilia is a education organization based out in Modena, Italy. It is known for research contribution in the topics: Population & Transplantation. The organization has 8179 authors who have published 22418 publications receiving 671337 citations. The organization is also known as: Università degli Studi di Modena e Reggio Emilia & Universita degli Studi di Modena e Reggio Emilia.
Topics: Population, Transplantation, Stem cell, Cancer, Breast cancer
Papers published on a yearly basis
Papers
More filters
••
University of Miami1, University of Hong Kong2, Charité3, University of California, San Francisco4, University of Milan5, Hannover Medical School6, Goethe University Frankfurt7, Université de Montréal8, University of Pittsburgh9, University of Padua10, University of Michigan11, University of Genoa12, University of Tennessee13, Mayo Clinic14, University of Kentucky15, Auckland City Hospital16, University of Modena and Reggio Emilia17, Université catholique de Louvain18, University of Pisa19, Lahey Hospital & Medical Center20, Leipzig University21, Royal Prince Alfred Hospital22, University College London23, Cambridge University Hospitals NHS Foundation Trust24, Ghent University25, Royal Adelaide Hospital26, Cedars-Sinai Medical Center27, Toronto General Hospital28, Scripps Health29, University of Alberta30, University of Santiago de Compostela31, Sapienza University of Rome32, University of Hamburg33, University of Iowa34, Virginia Commonwealth University35, University of Melbourne36, University of Udine37, University of Bologna38, Ludwig Maximilian University of Munich39, Erasmus University Rotterdam40
TL;DR: Adefovir dipivoxil is effective and safe in wait‐listed or post–liver transplantation chronic hepatitis B patients with lamivudine‐resistant HBV and prevents graft reinfection with or without HBIg.
232 citations
••
TL;DR: The first worldwide case of Usutu virus (USUV) neuroinvasive infection in a patient with diffuse large B cell lymphoma who presented with fever and neurological symptoms and was diagnosed with meningoencephalitits is reported.
Abstract: We report the first worldwide case of Usutu virus (USUV) neuroinvasive infection in a patient with diffuse large B cell lymphoma who presented with fever and neurological symptoms and was diagnosed with meningoencephalitits. The cerebrospinal fluid was positive for USUV, and USUV was also demonstrated in serum and plasma samples by RT-PCR and sequencing. Partial sequences of the premembrane and NS5 regions of the viral genome were similar to the USUV Vienna and Budapest isolates.
232 citations
••
TL;DR: This review, analyzing the main clinical studies, aims at being a state of the art update of the use of probiotic formulations in daily practice, and seems to be particularly useful to ease post-operative complications.
232 citations
••
TL;DR: The finding that the acidic precursor of CBD (cannabidiolic acid, CBDA) is able to inhibit the migration of breast cancer cells and to downregulate the proto-oncogene c-fos and the cyclooxygenase-2 (COX-2) highlights the possibility that CBDA might act on a common pathway of inflammation and cancer mechanisms, which might be responsible for its anticancer activity.
Abstract: In the last decades, a lot of attention has been paid to the compounds present in medicinal Cannabis sativa L., such as Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), and their effects on inflammation and cancer-related pain. The National Cancer Institute (NCI) currently recognizes medicinal C. sativa as an effective treatment for providing relief in a number of symptoms associated with cancer, including pain, loss of appetite, nausea and vomiting, and anxiety. Several studies have described CBD as a multitarget molecule, acting as an adaptogen, and as a modulator, in different ways, depending on the type and location of disequilibrium both in the brain and in the body, mainly interacting with specific receptor proteins CB1 and CB2. CBD is present in both medicinal and fibre-type C. sativa plants, but, unlike Δ9-THC, it is completely nonpsychoactive. Fibre-type C. sativa (hemp) differs from medicinal C. sativa, since it contains only few levels of Δ9-THC and high levels of CBD and related nonpsychoactive compounds. In recent years, a number of preclinical researches have been focused on the role of CBD as an anticancer molecule, suggesting CBD (and CBD-like molecules present in the hemp extract) as a possible candidate for future clinical trials. CBD has been found to possess antioxidant activity in many studies, thus suggesting a possible role in the prevention of both neurodegenerative and cardiovascular diseases. In animal models, CBD has been shown to inhibit the progression of several cancer types. Moreover, it has been found that coadministration of CBD and Δ9-THC, followed by radiation therapy, causes an increase of autophagy and apoptosis in cancer cells. In addition, CBD is able to inhibit cell proliferation and to increase apoptosis in different types of cancer models. These activities seem to involve also alternative pathways, such as the interactions with TRPV and GRP55 receptor complexes. Moreover, the finding that the acidic precursor of CBD (cannabidiolic acid, CBDA) is able to inhibit the migration of breast cancer cells and to downregulate the proto-oncogene c-fos and the cyclooxygenase-2 (COX-2) highlights the possibility that CBDA might act on a common pathway of inflammation and cancer mechanisms, which might be responsible for its anticancer activity. In the light of all these findings, in this review we explore the effects and the molecular mechanisms of CBD on inflammation and cancer processes, highlighting also the role of minor cannabinoids and noncannabinoids constituents of Δ9-THC deprived hemp.
231 citations
••
TL;DR: Preliminary results from a phase II clinical trial have shown improved clinical outcome and also changes consistent with a reduction of EMT, leading to the clinical investigation of the TGF-β inhibitor LY2157299 monohydrate in hepatocellular carcinoma.
Abstract: Hepatocellular carcinoma arises in patients as a consequence of long-standing preexisting liver illnesses, including viral hepatitis, alcohol abuse, or metabolic disease. In such preexisting liver diseases, TGF-β plays an important role in orchestrating a favorable microenvironment for tumor cell growth and promoting epithelial-mesenchymal transition (EMT). TGF-β signaling promotes hepatocellular carcinoma progression by two mechanisms: first, via an intrinsic activity as an autocrine or paracrine growth factor and, second, via an extrinsic activity by inducing microenvironment changes, including cancer-associated fibroblasts, T regulatory cells, and inflammatory mediators. Although there is an increasing understanding on how TGF-β signaling is associated with tumor progression in hepatocellular carcinoma, it is not clear whether TGF-β signaling is limited to a certain subgroup of patients with hepatocellular carcinoma or is a key driver of hepatocellular carcinoma during the entire tumorigenesis of hepatocellular carcinoma. Inhibitors of the TGF-β signaling have been shown to block hepatocellular carcinoma growth and progression by modulating EMT in different experimental models, leading to the clinical investigation of the TGF-β inhibitor LY2157299 monohydrate in hepatocellular carcinoma. Preliminary results from a phase II clinical trial have shown improved clinical outcome and also changes consistent with a reduction of EMT.
231 citations
Authors
Showing all 8322 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carlo M. Croce | 198 | 1135 | 189007 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Peter M. Rothwell | 134 | 779 | 67382 |
Claudio Franceschi | 120 | 856 | 59868 |
Lorenzo Galluzzi | 118 | 477 | 71436 |
Leonardo M. Fabbri | 109 | 566 | 60838 |
David N. Reinhoudt | 107 | 1082 | 48814 |
Stefano Pileri | 100 | 635 | 43369 |
Andrea Bizzeti | 99 | 1168 | 46880 |
Brian K. Shoichet | 98 | 281 | 40313 |
Dante Gatteschi | 97 | 727 | 48729 |
Roberta Sessoli | 95 | 424 | 41458 |
Thomas A. Buchholz | 93 | 494 | 33409 |
Pier Luigi Zinzani | 92 | 857 | 35476 |